摘要
The prognostic and predictive value of KRAS mutations in patients with lung cancer is controversial. Biases in disease stage, treatment regimen, small-scale patient studies, and biomarker status have led to inconsistent results in previous reports. <br>The KRAS and EGFR genes were examined in 1935 consecutive patients with non-small cell lung cancer. All patients were divided into KRAS mutation (KRAS group), EGFR mutation (EGFR group), and KRAS/EGFR wild type (WT group) groups. Randomly selected cases were paired with patients with the KRAS mutation, the EGFR mutation, and KRAS/EGFR wild type patients according to tumor, node, metastasis stage, time of first visit within 1 year, and pathology. Progression-free survival (PFS) and overall survival were evaluated by Kaplan-Meier and Cox models. <br>The KRAS mutation rate for lung adenocarcinoma was 5.90 %. The overall survival was 14.47, 20.57, and 42.73 months for the KRAS group, WT group, and EGFR group, respectively (P < 0.001). Multivariate analysis indicated that KRAS mutation status was an independent prognostic factor (hazard ratio 2.69, 95 % confidence interval 1.91-3.80, P < 0.001). No difference was found in PFS and tumor responsiveness between patients with a KRAS mutation and those with wild type KRAS/EGFR for chemotherapy and EGFR tyrosine kinase inhibitors (TKI). PFS did not significantly differ for chemotherapy among the three groups (P = 0.270). <br>KRAS mutation is a poor prognosis factor, but it is not an independent predictor of response to EGFR-TKI or chemotherapy in patients with lung cancer.
- Clinical characteristics and prognostic value of theKRAS G12Cmutation in Chinese non-small cell lung cancer patientsLiu, Si-Yang; Sun, Hao; Zhou, Jia-Ying; Jie, Guang-Ling; Xie, Zhi; Shao, Yang; Zhang, Xian; Ye, Jun-Yi; Chen, Chun-Xiang; Zhang, Xu-Chao; Zhou, Qing; Yang, Jin-Ji; Wu, Yi-Long*Biomarker Research, 2020, 8(1): 22.被引 38
- Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical TrialLi, Xiang-Meng; Li, Wen-Feng; Lin, Jun-Tao; Yan, Hong-Hong; Tu, Hai-Yan; Chen, Hua-Jun; Wang, Bin-Chao; Wang, Zhen; Zhou, Qing; Zhang, Xu-Chao; Su, Jian; Chen, Rui-Lian; Wu, Yi-Long*; Yang, Jin-Ji*Clinical Lung Cancer, 2021, 22(2): 100-+.被引 28
- KRAS modulates immune infiltration levels and survival outcomes in patients with lung adenocarcinomaLi, Na; Tian, Yue; Liu, Xin; Pan, Ciming; Xue, Jian*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2023, 102(52): e36597.
